PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 30, 2025Frontiers in Immunology0 citationsOpen Access

Astragalus polysaccharides: structure-immunomodulation relationships, multi-target pharmacological activities, and cutting-edge applications in immune modulation

View Full Paper
BWBo WangBWBanglong WuYMYingjuan Ma

Key Points

  • Immunomodulatory properties of astragalus polysaccharides are influenced by specific molecular weight and monosaccharide ratios.
  • Key mechanisms involve engagement with immune receptors like Toll-like receptor 4 and other pattern recognition receptors.
  • Research emphasizes the importance of standardization and quality control for clinical applications of astragalus polysaccharides.
  • Future clinical studies should focus on mapping receptor-binding sites to advance aps into a therapeutic agent.

Abstract

Astragalus Polysaccharide (APS), the primary bioactive component of Astragalus, exhibits multi-faceted immunomodulatory properties. Its efficacy stems not from broad, non-specific stimulation but from the precise engagement of a network of cell surface immune receptors. This review synthesizes the critical structure-immunomodulatory network relationship of APS, positioning Toll-like receptor 4 as a central mediator. Key insights reveal that APS bioactivity is governed by a specific molecular weight window, critical monosaccharide ratios, and distinct glycosidic linkages. These structural features enable APS to interact with TLR4, potentially in collaboration with other pattern recognition receptors such as the Mannose Receptor and Dectin-1, to initiate integrated signaling. Future research must prioritize multi-omics and structural biology to map precise receptor-binding sites, establish robust standardization and quality control protocols, and advance translational clinical studies for APS-based adjuvant development. This work provides a strategic framework for advancing APS from a traditional remedy into a novel, mechanism-driven immunomodulatory agent.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/692b9d7b1d383f2b2a3795behttps://doi.org/10.3389/fimmu.2025.1714898
Ask AI
Helpful
Bookmark
Share
View Full Paper